CJC-1295 (with DAC) vs CJC-1295 (without DAC)

CJC-1295 (with DAC)

CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analogue conjugated with a maleimidopropionic acid (MPA) linker that binds covalently to serum albumin after injection. This albumin conjugation dramatically extends the peptide's half-life from approximately 30 minutes to 6-8 days, enabling sustained elevation of growth hormone levels from a single administration. The mechanism involves the same GHRH receptor activation as the non-DAC version, but the prolonged pharmacokinetic profile produces continuous rather than pulsatile GH stimulation. In a pivotal pharmacokinetic study, Teichman et al. (Journal of Clinical Endocrinology and Metabolism, 2006) demonstrated that a single 60 mcg/kg subcutaneous dose of CJC-1295 with DAC produced sustained GH elevation for 6-14 days and elevated IGF-1 levels for 9-11 days in healthy adult subjects, with a 1.5 to 2-fold increase in mean GH concentrations. This sustained profile is both an advantage and a consideration: while it reduces dosing frequency, the continuous GH elevation does not replicate the natural pulsatile pattern of endogenous GH secretion. Compared to CJC-1295 without DAC, the DAC version is suited for research protocols requiring prolonged GH axis stimulation, while the non-DAC form better models physiological pulse dynamics. Research also suggests potential applications in lean mass preservation, bone mineral density, and sleep quality improvement through sustained GH pathway activation. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 28 days. This compound is studied by endocrinology research programs, pharmacokinetics laboratories, and institutions investigating sustained-release peptide delivery strategies.

CJC-1295 (without DAC)

CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF) is a synthetic 29-amino acid peptide analogue of growth hormone-releasing hormone (GHRH) with four amino acid substitutions (positions 2, 8, 15, and 27) that confer resistance to DPP-IV enzymatic degradation. Its mechanism of action involves binding to GHRH receptors (GHRH-R) on anterior pituitary somatotroph cells, stimulating cAMP-mediated signaling that triggers growth hormone synthesis and secretion. The amino acid modifications extend the peptide's biological half-life from under 10 minutes (native GHRH) to approximately 30 minutes, enabling meaningful GH pulse amplification while still preserving physiological pulsatile release patterns. Research on this modified GHRH analogue demonstrates it produces GH elevations within 15-30 minutes of administration, with return to baseline within 2-3 hours, mimicking natural GH pulse kinetics. Studies suggest CJC-1295 without DAC may support skin thickness and collagen production through GH-mediated IGF-1 elevation (Ionescu and Bhatt, Growth Hormone and IGF Research). Compared to the DAC-conjugated version (CJC-1295 with DAC), the non-DAC form produces shorter, more discrete GH pulses rather than sustained 7-10 day GH elevation, which some research protocols prefer for mimicking physiological patterns. It is frequently paired with ghrelin mimetics like ipamorelin for synergistic effect. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 21 days. This peptide is studied by endocrinology research departments, anti-aging medicine laboratories, and body composition research centers investigating GHRH axis modulation.

Frequently Asked Questions